ASTELLAS PHARMA A/S: Financial statements 2024
CVR: 10888638
Source: annual report 2024, Danish Business Authority
01/04/2023 – 31/03/2024
ASTELLAS PHARMA A/S (CVR 10888638) has filed annual accounts for 2024. In 2024, the company reported revenue of EUR 186,855,000 and a net result of EUR 4,470,000 compared with EUR 2,081,000 the year before. That is an increase of 3.3% compared with the year before. The profit margin was 2.4%. Equity in the 2024 report amounted to EUR 24,696,000. The solvency ratio was 24.5%. The company had 97 employees in the financial year.
- Revenue
- EUR 186,855,000
- Gross Profit
- EUR 20,887,000
- Profit/Loss
- EUR 4,470,000
- Equity
- EUR 24,696,000
- Total Assets
- EUR 100,770,000
- Employees
- 97
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | 186.9M EUR | 20.9M EUR | 4.5M EUR | 24.7M EUR | 97 |
| 2023 | 180.8M EUR | 23.1M EUR | 2.1M EUR | 35.3M EUR | 120 |
| 2022 | 179.9M EUR | 26.2M EUR | 6.7M EUR | 58.2M EUR | 120 |
| 2021 | 160.5M EUR | 24.1M EUR | 5.9M EUR | 59.4M EUR | 115 |
| 2020 | 187M EUR | 23.8M EUR | 2M EUR | 53.6M EUR | 114 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
ASTELLAS PHARMA A/S has won the tender "Amgros 2025 1.1162.a" issued by Amgros I/S worth 1,689,600,000 DKK.
ASTELLAS PHARMA A/S has won the tender "Amgros 2025 1.980.a" issued by Amgros I/S worth 48,000,000 DKK.
ASTELLAS PHARMA A/S has won the tender "Amgros 2024 1.150.a" issued by Amgros I/S worth 73,756,763 DKK.
About ASTELLAS PHARMA A/S
ASTELLAS PHARMA A/S is a Danish company of the type Aktieselskab based in København S, founded in 1987. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named YAMANOUCHI PHARMA A/S and BROCADES PHARMA A/S. The management consists of Mark Andree Dekker. The board consists of Damla Ebru Atilgan (chair), Anne Nymand, Giuseppe Maduri and Mark Andree Dekker. The company is owned by Astellas Pharma Europe LTD.. The company has 67 employees (2026). In 2026, the company reported revenue of EUR 197,863,000 and a net result of EUR 5,229,000 compared with EUR 5,705,000 the year before. Equity in the 2026 report amounted to EUR 20,071,000.